[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oculis Holding Ag (OCS)

Oculis Holding Ag (OCS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 650,001
  • Shares Outstanding, K 57,984
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -119,440 K
  • EBIT $ -104 M
  • EBITDA $ -103 M
  • 60-Month Beta 0.23
  • Price/Sales 474.05
  • Price/Cash Flow N/A
  • Price/Book 2.73

Options Overview Details

View History
  • Implied Volatility 131.83% (-14.92%)
  • Historical Volatility 166.58%
  • IV Percentile 37%
  • IV Rank 40.80%
  • IV High 205.40% on 05/26/26
  • IV Low 81.11% on 04/15/26
  • Expected Move (DTE 11) 0.04 (0.38%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 128
  • Volume Avg (30-Day) 610
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 6,767
  • Open Int (30-Day) 4,123
  • Expected Range 11.17 to 11.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.48
  • Number of Estimates 4
  • High Estimate $-0.45
  • Low Estimate $-0.51
  • Prior Year $-0.59
  • Growth Rate Est. (year over year) +18.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.17 +0.36%
on 06/05/26
34.47 -67.48%
on 05/11/26
-16.54 (-59.60%)
since 05/05/26
3-Month
11.17 +0.36%
on 06/05/26
34.47 -67.48%
on 05/11/26
-16.53 (-59.59%)
since 03/05/26
52-Week
11.17 +0.36%
on 06/05/26
34.47 -67.48%
on 05/11/26
-8.35 (-42.69%)
since 06/05/25

Most Recent Stories

More News
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ:...

OCS : 11.21 (-5.24%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to...

OCS : 11.21 (-5.24%)
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud

Oculis Holding AG shares lost over 23% of their value in a single session after Phase 3 DIAMOND trial results revealed OCS-01 failed to meet its primary endpoint in diabetic macular edema.

OCS : 11.21 (-5.24%)
OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations

Oculis Holding AG claimed its "most important" drug, OSC-01, was biologically approved months before revealing the Phase 3 Diamond studies concerning the drug had failed to achieve their primary endpoints....

OCS : 11.21 (-5.24%)
Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)

Oculis Holding AG SEC filings continued to describe the OCS-01 DME program as on track for FDA submission after Phase 3 DIAMOND trials had already failed -- shares fell over 23%

OCS : 11.21 (-5.24%)
OCS ALERT: Levi & Korsinsky Investigates Oculis Holding AG for Possible Securities Fraud Violations

New York, New York--(Newsfile Corp. - June 1, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Oculis Holding AG ("Oculis Holding AG") (NASDAQ: OCS) concerning potential...

OCS : 11.21 (-5.24%)
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals

Oculis (NASDAQ:OCS) said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug...

OCS : 11.21 (-5.24%)
S&P 500 and Dow Rally to Record Highs as Tech Stocks Surge

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.62%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.99%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.94%. March E-mini...

TT : 456.84 (-1.27%)
AMAT : 453.01 (-9.71%)
MPC : 262.01 (-1.89%)
B : 39.46 (-7.78%)
SNDK : 1,559.32 (-11.39%)
HL : 14.78 (-12.18%)
CVX : 187.31 (-0.55%)
CDE : 16.37 (-11.42%)
ADI : 401.39 (-6.38%)
AXON : 486.12 (-5.28%)
TXN : 285.06 (-6.65%)
$IUXX : 28,957.60 (-4.77%)
Stocks Supported by AI Investment and Strength in Miners

The S&P 500 Index ($SPX ) (SPY ) today is up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.49%. March E-mini S&P futures (ESH26...

TT : 456.84 (-1.27%)
CARR : 67.16 (-2.01%)
B : 39.46 (-7.78%)
SNDK : 1,559.32 (-11.39%)
HL : 14.78 (-12.18%)
CDE : 16.37 (-11.42%)
ADI : 401.39 (-6.38%)
TXN : 285.06 (-6.65%)
$IUXX : 28,957.60 (-4.77%)
ZNU26 : 109-025s (-0.47%)
AEVA : 23.01 (-5.70%)
ESM26 : 7,400.50s (-2.64%)
Stocks Edge Higher on Strength in Chip Makers and Data Storage Companies

The S&P 500 Index ($SPX ) (SPY ) today is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.63%. March E-mini S&P futures (ESH26...

TT : 456.84 (-1.27%)
AMAT : 453.01 (-9.71%)
CARR : 67.16 (-2.01%)
B : 39.46 (-7.78%)
SNDK : 1,559.32 (-11.39%)
HL : 14.78 (-12.18%)
CDE : 16.37 (-11.42%)
TXN : 285.06 (-6.65%)
$IUXX : 28,957.60 (-4.77%)
ZNU26 : 109-025s (-0.47%)
AEVA : 23.01 (-5.70%)
ESM26 : 7,400.50s (-2.64%)

Business Summary

Oculis Holding AG is a biopharmaceutical company which develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidate includes OCS-01, OCS-02 and OCS-05. Oculis Holding AG is based in Zug, Switzerland.

See More

Key Turning Points

3rd Resistance Point 12.65
2nd Resistance Point 12.35
1st Resistance Point 11.78
Last Price 11.21
1st Support Level 10.90
2nd Support Level 10.60
3rd Support Level 10.03

See More

52-Week High 34.47
Fibonacci 61.8% 25.57
Fibonacci 50% 22.82
Fibonacci 38.2% 20.07
Last Price 11.21
52-Week Low 11.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.